Published in Ann Pharmacother on March 23, 2010
An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol (2012) 1.39
Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol (2015) 0.92
Oleanolic acid alters bile acid metabolism and produces cholestatic liver injury in mice. Toxicol Appl Pharmacol (2013) 0.90
Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality. Br J Clin Pharmacol (2015) 0.84
Optimizing chemotherapy: concomitant medication lists. Clin Pharmacol Ther (2010) 0.78
Review of cases of patient risk associated with ginseng abuse and misuse. J Ginseng Res (2014) 0.76
Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account. J Cancer Res Clin Oncol (2016) 0.75
Ginseng for Liver Injury: Friend or Foe? Medicines (Basel) (2016) 0.75
Interactions of 172 plant extracts with human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8): a study on herb-drug interactions. PeerJ (2017) 0.75
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol (2013) 7.81
Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr (2013) 2.94
Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut (2012) 2.65
Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr (2011) 2.49
The transcriptional diversity of 25 Drosophila cell lines. Genome Res (2010) 2.47
Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N Engl J Med (2014) 2.06
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
Geographical variation and incidence of inflammatory bowel disease among US women. Gut (2012) 1.85
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood (2013) 1.71
Measures of obesity and risk of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2015) 1.66
Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.57
QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis (2011) 1.55
Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. Gastroenterology (2012) 1.27
Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. BMJ (2013) 1.18
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis (2014) 1.08
Modeling disease severity in multiple sclerosis using electronic health records. PLoS One (2013) 1.06
Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol (2013) 1.05
Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.03
Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. Inflamm Bowel Dis (2014) 1.03
Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol (2012) 1.02
State of Adult Trainee Inflammatory Bowel Disease Education in the United States: A National Survey. Inflamm Bowel Dis (2016) 1.00
Deleterious effect of cirrhosis on outcomes after motor vehicle crashes using the nationwide inpatient sample. Am J Gastroenterol (2008) 0.96
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res (2009) 0.95
A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg (2010) 0.90
Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl (2012) 0.90
Improving the power of genetic association tests with imperfect phenotype derived from electronic medical records. Hum Genet (2014) 0.89
Early life factors and risk of inflammatory bowel disease in adulthood. Inflamm Bowel Dis (2013) 0.87
Endogenous levels of circulating androgens and risk of Crohn's disease and ulcerative colitis among women: a nested case-control study from the nurses' health study cohorts. Inflamm Bowel Dis (2015) 0.86
Association between low density lipoprotein and rheumatoid arthritis genetic factors with low density lipoprotein levels in rheumatoid arthritis and non-rheumatoid arthritis controls. Ann Rheum Dis (2013) 0.86
Natural history of Crohn's disease following total colectomy and end ileostomy. Inflamm Bowel Dis (2014) 0.85
Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci (2011) 0.85
Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis (2009) 0.83
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis (2014) 0.83
Myelodysplastic syndromes in the United States: an update for clinicians. Ann Med (2014) 0.83
Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol (2009) 0.83
Chronic myelogenous leukemia for primary care physicians. Dis Mon (2012) 0.82
Impact of mode of delivery on outcomes in patients with perianal Crohn's disease. Inflamm Bowel Dis (2014) 0.81
Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease. Inflamm Bowel Dis (2010) 0.80
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med (2007) 0.79
Natural history of perianal Crohn's disease after fecal diversion. Inflamm Bowel Dis (2014) 0.79
Clostridium difficile Infection and Risk of Colectomy in Patients with Inflammatory Bowel Disease: A Bias-adjusted Meta-analysis. Inflamm Bowel Dis (2017) 0.79
High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.79
Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol (2012) 0.78
Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis (2009) 0.78
Myeloproliferative neoplasms. Dis Mon (2012) 0.77
Missed polyps, missed opportunities. Gastrointest Endosc (2011) 0.77
Resolution of rheumatoid arthritis symptoms with imatinib mesylate. J Clin Rheumatol (2009) 0.77
Vitamin D and IBD: more pieces to the puzzle, still no complete picture. Inflamm Bowel Dis (2011) 0.76
Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link? Leuk Res (2006) 0.76
Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. Leuk Lymphoma (2010) 0.76
Nilotinib cardiac toxicity: should we still be concerned? Leuk Res (2011) 0.76
Dyssynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in remission. Dig Dis Sci (2013) 0.76
Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. Inflamm Bowel Dis (2016) 0.75
Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study. Inflamm Bowel Dis (2016) 0.75
Older Age- and Health-related Quality of Life in Inflammatory Bowel Diseases. Inflamm Bowel Dis (2017) 0.75
Rising Educators, Academicians, and Clinicians Helping Inflammatory Bowel Disease (REACH-IBD)-Promoting Improvement of Inflammatory Bowel Disease Education in the United States. Inflamm Bowel Dis (2016) 0.75
Reply: To PMID 24088707. JPEN J Parenter Enteral Nutr (2014) 0.75
Environmental Hygiene and Risk of Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2016) 0.75
Depression but Not Symptom Severity is Associated With Work and School Absenteeism in Refractory Chronic Constipation. J Clin Gastroenterol (2017) 0.75
Dietary Iron and Heme Iron Consumption, Genetic Susceptibility, and Risk of Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis (2017) 0.75
Recurrent deep vein thrombosis and pulmonary embolism in a young man with Klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298A>C. Blood Coagul Fibrinolysis (2010) 0.75
Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease. Inflamm Bowel Dis (2017) 0.75
Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. Int J Dermatol (2012) 0.75
The exposome in inflammatory bowel disease. Trop Gastroenterol (2015) 0.75
Erratum: A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nat Commun (2016) 0.75